# A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

> **NCT04173273** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 375 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Etrasimod
- **DRUG:** Etrasimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04173273
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-06
- **Primary completion:** 2025-04-23
- **Final completion:** 2025-06-09
- **Target enrollment:** 375 (ACTUAL)
- **Why stopped:** The study was prematurely discontinued due to a lack of efficacy in sub-study 1
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04173273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04173273, "A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04173273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*